{
    "Clinical Trial ID": "NCT00479674",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Abraxane, Carboplatin, Bevacizumab",
        "  Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15",
        "  Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..",
        "  Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.",
        "  Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Tissue block containing tumor to confirm metastatic breast cancer is required;",
        "  Measurable disease according to RECIST criteria",
        "  \"Triple negative\" disease defined as tumor demonstrating no expression for estrogen, progesterone or human epidermal growth factor receptor 2(HER2)receptors. \"No expression\" is categorized as  10% of cells staining or Allred  2;",
        "  Aged 18 years or older;",
        "  Eastern Cooperative Oncology Group (ECOG)/Zubrod performance status of 0 or 1; life expectancy  3 months;",
        "  Patients may have received 0 - 1 prior therapies (except taxanes in the metastatic setting). An interval of at least 1 week must have elapsed since prior chemotherapy or hormonal therapy for metastatic disease; at least 6 months must have elapsed since prior adjuvant therapy;",
        "   2 weeks between surgery and study enrollment ( 4 weeks between major surgery (defined as open abdominal/thoracic/cardiac) and study enrollment;",
        "  Laboratory tests performed within 14 days of study entry:",
        "  Granulocytes  1,500/\u00b5L;",
        "  Platelets  100,000/\u00b5L;",
        "  Hemoglobin  9 gm/dL;",
        "  Total bilirubin  institutional upper limit of normal (ULN);",
        "  Aspartate transaminase (AST) and alanine aminotransferase (ALT)  5 times ULN;",
        "  Alkaline phosphatase  2.5 times ULN;",
        "  Estimated creatinine clearance  60 mL/min.",
        "  left ventricular ejection fraction (LVEF) 50% by multigated acquisition (MUGA)/Echocardiogram;",
        "  Informed consent to receive protocol treatment, to provide biologic specimens, and to complete neurotoxicity questionnaires;",
        "  Cognitive and communication skills to comply with study and/or follow-up procedures;",
        "  No reproductive potential:",
        "  If pre-menopausal: Negative serum pregnancy test and patient agreement to use adequate contraceptive method (abstinence, intrauterine device, barrier device with spermicide or surgical sterilization) during and for 3 months after completion of treatment.",
        "If post-menopausal: Amenorrhea for  12 months.",
        "Exclusion Criteria:",
        "  Pregnant or breast feeding;",
        "  Prior treatment with Abraxane\u00ae, carboplatin or bevacizumab, or any taxane for metastatic breast cancer;",
        "  Known hypersensitivity to any component of any study drug;",
        "  Active infection;",
        "  Current neuropathy  grade 2;",
        "  central nervous system (CNS) metastases as determined by head CT with contrast;",
        "  History of bleeding within the past 6 months or active bleeding disorder;",
        "  Serious non-healing wound, ulcer or bone fracture;",
        "  Uncontrolled congestive heart failure (CHF), or history of myocardial infarction(MI), unstable angina, stroke, or transient ischemia within previous 6 months;",
        "  Inadequately controlled hypertension (defined as systolic blood pressure < 150 and/or diastolic blood pressure > 100 mmHg on antihypertensive medications; prior history of hypertensive crisis or hypertensive encephalopathy;",
        "  Proteinuria (defined as urine protein: creatinine (UPC) ratio  1.0 or urine dipstick  2+.",
        "  Significant vascular disease (aortic aneurysm, aortic dissection) or symptomatic peripheral vascular disease;",
        "  History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within previous 6 months;",
        "  Uncontrolled serious contraindicated medical condition or psychiatric illness."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Best Clinical Response Expressed as Percentage of Participants Treated With Combination Regimen of Weekly Abraxane\u00ae and Carboplatin Plus Biweekly Bevacizumab to Treat Women With Stage IV or Inoperable Stage III \"Triple Negative\" Metastatic Breast Cancer.",
        "  Best clinical response is based on RECIST criteria, the proportion in each response category along with the exact binomial confidence intervals are estimated. Toxicity summaries are also provided.",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Abraxane, Carboplatin, Bevacizumab",
        "  Arm/Group Description: Abraxane 100 mg/m2 IV over 30 min days 1,8,15.; Carboplatin AUC=2 IV over 15 min days 1,8,15., Bevacizumab 10 mg/kg IV days 1,15",
        "  Abraxane: 100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..",
        "  Bevacizumab: 10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.",
        "  Carboplatin: area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.",
        "  Overall Number of Participants Analyzed: 39",
        "  Measure Type: Number",
        "  Unit of Measure: percentage of participants  Complete Response: 18        (8 to 34)",
        "  Partial Response: 69        (52 to 83)",
        "  Stable Disease: 8        (2 to 21)",
        "  Progressive Disease: 5        (1 to 17)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 22/41 (53.66%)",
        "  Anemia 1/41 (2.44%)",
        "  Dyspepsia 1/41 (2.44%)",
        "  Mucositis oral 1/41 (2.44%)",
        "  Nausea 3/41 (7.32%)",
        "  Vomiting 1/41 (2.44%)",
        "  Pain 3/41 (7.32%)",
        "  Allergic reaction 1/41 (2.44%)",
        "  Infections and infestations - Other, specify:  [1]1/41 (2.44%)",
        "  Vascular access complication 3/41 (7.32%)",
        "  Alanine aminotransferase increased 1/41 (2.44%)"
    ]
}